Every row of the evidence table

A threshold-derivation meta-analysis: it converges on 18 Centiloids (data-driven) and 27 Centiloids (visual reads) and flags 11-26 as a range to read with caution. It compares no exposure, so no direction exists to record.

Appropriate use criteria rated by consensus: for amyloid PET seven of 17 scenarios were rated appropriate, two uncertain and eight rarely appropriate; for tau PET five, six and six. No effect estimate is reported.

An editorial reviewing the FDA clearance of the Lumipulse plasma ratio test. It relays performance figures from the FDA summary and other studies and reports no data of its own.

A clinical practice guideline. It sets performance thresholds for blood tests (at least 90% sensitivity and 75% specificity for triage; at least 90% for both to substitute for amyloid PET or CSF) and reports no effect estimate of its own.

A price-threshold model: it estimates the test price at which diagnostic cost per true-positive case equals standard care ($290-$1,950 depending on use), and compares no actual price against it, so there is no direction to record.

A workgroup recommendations document. It sets target sensitivity and specificity for blood biomarker tests (≥90% / ≥85% for triage in primary care; ~90% / ~90% as a confirmatory test) and reports no data of its own.

A pooled prevalence among carers (50.8% lonely, 37.1% socially isolated) with no non-carer comparison, so no direction for the effect of caregiving can be recorded.

A cost estimate ($818 billion, 80% of it borne by families through unpaid care, earnings losses, out-of-pocket costs and quality-of-life losses) with no exposure compared, so no direction is recorded.

A descriptive spending analysis with no exposure compared, so there is no direction to record: Part D spending rose with dual-eligibility duration, Part B drug spending varied widely by state, and ACO enrollment made only a modest difference.

A cost projection: total burden is estimated at $344 billion in 2020 rising to over $3 trillion in 2060, with African American and Latino families projected to bear a disproportionate share. It compares spending shares between groups but tests no exposure, so no direction is recorded.

A cost estimate with no exposure compared, so there is no direction to record. Higher unpaid-care costs went with lower medical spending on nursing facility care.

A cost projection with no exposure compared, so there is no direction to record. Dementia's share of replacement cost is projected to rise from 44% to 53%.

A cost estimate with no exposure compared, so there is no direction to record.

A cost estimate and projection with no exposure compared, so there is no direction to record.

A cost estimation across 204 countries with no exposure compared, so there is no direction to record.

A threshold analysis estimating what each country should be willing to pay (from $4-$18 a year in low-income countries to $254-$9,434 for lecanemab and $387-$13,964 for donanemab in high-income countries). It sets no price against an actual list price, so there is no direction to record.

A cost-effectiveness model reporting ICERs of JPY 8.5 million and 7.9 million per QALY without stating a threshold or a verdict; the authors argue that narrow value assessments understate social value. No direction is recorded.

A criteria document. It defines Alzheimer's disease biologically and sets out staging, and reports no effect estimate.

An editorial. It argues that biomarker positivity alone should not define Alzheimer's disease in people without symptoms, and reports no data of its own.

A research framework defining Alzheimer's disease by biomarkers (the AT(N) system) for research use. It states its own intended limits and reports no effect estimate.

Consensus guidance for primary care on disclosing and communicating a dementia diagnosis, developed with patients, care partners and clinicians. It reports no effect estimate.

A clinical practice guideline. It sets out a structured, patient-centred process for evaluating, diagnosing and disclosing suspected Alzheimer's disease or related dementias in any practice setting, and reports no effect estimate.

A single-programme implementation report with no comparison group. It counts enrolment and service use and estimates no effect.

Implementation guidance drawn from six earlier comprehensive dementia care programmes. It reports no effect estimate of its own.

A classification-validation study without a neuropathological reference standard, so accuracy cannot be judged. The groups behaved as expected: patients labelled LATE had mild amnestic impairment, limbic atrophy and stable MMSE over 30 months, while AD and AD/LATE groups declined.

A Delphi consensus among 60 international expert panellists, reaching agreement on 15 major and 42 minor referral criteria. No patient outcome is measured and no effect is estimated.

A prognosis meta-analysis: it pools time to death and to nursing home admission and compares no exposure. Women's shorter survival was attributable to later age at diagnosis.